| 0.9684 -0.062 (-5.98%) | 09-28 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.49  |
1-year : | 1.74 |
| Resists | First : | 1.28 |
Second : | 1.49 |
| Pivot price | 1.14 |
|||
| Supports | First : | 0.94 |
Second : | 0.79 |
| MAs | MA(5) : | 1.04 |
MA(20) : | 1.21 |
| MA(100) : | 1.35 |
MA(250) : | 1.25 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 8.6 |
D(3) : | 9.1 |
| RSI | RSI(14): 29 |
|||
| 52-week | High : | 1.84 | Low : | 0.76 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ALLR ] has closed below the lower bollinger band by 2.4%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 4.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.09 - 1.09 | 1.09 - 1.1 |
| Low: | 0.93 - 0.94 | 0.94 - 0.95 |
| Close: | 0.96 - 0.97 | 0.97 - 0.98 |
Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new cancer treatments. They utilize a unique "drug response predictor" technology to generate specific companion diagnostics, aiming to identify which patients will best respond to their various oncology therapeutics. The company's portfolio of investigational drugs for various cancers includes: Stenoparib: A poly-ADP-ribose polymerase (PARP) inhibitor currently in Phase 2 clinical trials for ovarian cancer. Dovitinib: A pan-tyrosine kinase inhibitor designed to treat renal cell carcinoma. IXEMPRA: A microtubule inhibitor used in the treatment of metastatic breast cancer. LiPlaCis: A liposomal formulation of cisplatin, undergoing Phase 2 clinical trials for metastatic breast cancer. 2X-111: A liposomal formulation of doxorubicin, also in Phase 2 studies for both metastatic breast cancer and glioblastoma multiforme. Established in 2004, Allarity Therapeutics maintains its headquarters in Cambridge, Massachusetts.
Mon, 28 Sep 2026
Allarity Therapeutics Expands Laboratory Capabilities to Include Proteomics and Cell Line Research - Investing News Network
Mon, 28 Sep 2026
About 300 proteins involved in tumor signaling can now be studied at Allarity’s lab. - Stock Titan
Sun, 27 Sep 2026
Allarity Therapeutics (ALLR) Stock Analysis Report | Financials & Insights - Benzinga
Tue, 15 Sep 2026
Allarity Therapeutics Granted Japanese Patent for - GlobeNewswire
Mon, 14 Sep 2026
Allarity Therapeutics-backed SPAC files S-1 for $100M IPO; sponsor to hold ~25% - TradingView
Fri, 11 Sep 2026
Allarity Therapeutics Announces Strategic Capital Allocation for Filing of SPAC Registration Statement - Investing News Network
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 16 (M) |
| Held by Insiders | 1.586e+007 (%) |
| Held by Institutions | 4.1 (%) |
| Shares Short | 107 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.08e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -3 % |
| Return on Assets (ttm) | 128.9 % |
| Return on Equity (ttm) | -25.4 % |
| Qtrly Rev. Growth | 345000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -280.52 |
| EBITDA (p.s.) | 616071 |
| Qtrly Earnings Growth | -0.8 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -14 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 2.46 |
| Dividend | 0 |
| Forward Dividend | 111890 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|